Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy--
AKT/m-TOR Pathway and Resistance to Cancer Therapy

• Published in: Zhongguo fei ai za zhi Vol. 21; no. 1; pp. 63 - 66
• Main Authors: Spirina, Liudmila V, Kondakova, Irina V, Tarasenko, Natalia V, Slonimskaya, Elena M, Usynin, Evgeny A, Gorbunov, Alexey K, Yurmazov, Zahar A, Chigevskaya, Svetlana Yu
• Format: Journal Article
• Language: Chinese; English
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 20-01-2018; 中国肺癌杂志编辑部; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: AKT/m-TOR signaling pathway; Cancer therapies; Cell growth; Kinases; Mini-Review; Molecular markers; Prostate cancer; Resistance to cancer therapy; Thyroid cancer; 综述; Russia; Molecular markers; Resistance to cancer therapy; AKT/m-TOR signaling pathway
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2018.01.09

Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.